MAS
IOVA icon

Meeder Advisory Services’s Iovance Biotherapeutics IOVA Stock Holding History

Meeder Advisory Services’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,537
Closed -$31.5K – 683
2025
Q3 		$31.5K Sell
14,537
-12,733
-47% -$30.1K ﹤0.01% 623
2025
Q2 		$46.9K Buy
27,270
+12,062
+79% +$30K ﹤0.01% 609
2025
Q1 		$50.6K Buy
+15,208
New +$78.4K ﹤0.01% 569

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meeder Advisory Services's IOVA Position: Q4 2025 in Review

Meeder Advisory Services sold out of Iovance Biotherapeutics (IOVA) in Q4 2025, closing a stake of 14,537 shares — an estimated $31.5K sold.

Meeder Advisory Services first reported a position in IOVA in Q1 2025 and held it in 3 quarters. The position peaked at $50.6K in Q1 2025. 263 funds tracked by Wall St. Rank hold IOVA as of Q4 2025.

  • Meeder Advisory Services reported no remaining Iovance Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Meeder Advisory Services sold 14,537 Iovance Biotherapeutics shares in Q4 2025, an estimated $31.5K.
  • Meeder Advisory Services first reported a position in Iovance Biotherapeutics in Q1 2025 and held it in 3 quarters.
  • Meeder Advisory Services's Iovance Biotherapeutics position peaked at $50.6K in Q1 2025.
  • 263 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2025.

Based on Meeder Advisory Services's 13F filing for Q4 2025, filed 11 Feb 2026.